Global drug sales to hit $650 billion in 2006: IMS Health

Share this article:

Global pharmaceutical sales will grow by 7 percent in 2006, a slower pace than this year, with total market size reaching up to $650 billion, IMS Health reported yesterday.
The year 2006 "seems like a pretty pivotal year for the industry, the biggest year ever in terms of drugs likely to lose their patents in key markets," said Murray Aitken, IMS Health senior vice president, corporate strategy, in a pubished report.
Approximately $23 billion in products may lose patent protection overall next year. Sales of generics may rise to $45 billion, Aitken said.
Blockbuster drugs facing generic competition in key markets next year include Pfizer's antidepressant Zoloft, Sanofi-Aventis' insomnia treatment Ambien, Novartis' Lamisil for nail fungus and GlaxoSmithKlines's Zofran chemotherapy.
The U.S. market, which accounts for 43 percent of pharmaceutical sales worldwide, will continue to fuel growth in 2006.
IMS forecasted that the U.S. would grow at a 9 percent pace to $279 billion, up from an expected growth of 6 to 7 percent in 2005.
Increased access by U.S. seniors to lower-cost medications through Medicare Part D and a rebound from the impact of COX-2 product recalls and safety issues will help fuel growth, IMS said.

Share this article:

Email Newsletters

More in News

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union

Rep access continues to shrink

Rep access continues to shrink

Sales reps are experiencing even more limited physician access, according to a report by Chicago consultancy ZS Associates.

Allergan touts reorg, plans to lay off 13% of workforce

Allergan touts reorg, plans to lay off 13% ...

Allergan's second-quarter earnings, and a new round of cuts, are now part of the Botox maker's record as it seeks to remain independent.